Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool December 29, 2011 Matt Thalman	3 Companies That Give Back to Shareholders These three companies have consistently increased the value of each outstanding share: UPS... Johnson & Johnson... ExxonMobil...
The Motley Fool May 26, 2010 Brian Orelli	Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.
The Motley Fool June 17, 2008 Mac Greer	Fool Video: Sturdy Stocks and the Future of Satellite Radio Should investors expect big returns from the expected XM/Sirius merger? Can stocks like General Mills, Johnson & Johnson and Merck beat recession and inflation? These questions and others are answered in this video.
The Motley Fool January 8, 2008 Mac Greer	Fool Video: The Best Stock for 2008, Buffett's Latest, and Bear Market Buys Can Apple continue to produce? Will McDonald's serve up big earnings? Is 2008 the year for Johnson & Johnson? Will Starbucks continue to yield not-so-grande returns? These and other questions are answered in this video.
The Motley Fool June 22, 2011 Housel & Moscovitz	Live Blog: Bernanke on the Economy The boss talks.
The Motley Fool August 28, 2010 Todd Wenning	Dividend Report Card: Johnson & Johnson Does this health-care titan's dividend pass the test?
The Motley Fool October 17, 2006 Brian Lawler	See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
The Motley Fool February 28, 2011 Brian Orelli	Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo.
The Motley Fool January 26, 2011 Brian Orelli	J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot.
The Motley Fool August 11, 2010 David Meier	Does Bill Miller Think Johnson & Johnson Is Attractive? Johnson & Johnson fits Miller's criteria perfectly. It pays a 3.6% dividend that has been growing 11.1%, on average, for the past five years.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool July 20, 2010 Brian Orelli	Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
The Motley Fool June 28, 2011 Eric Bleeker	Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales?
The Motley Fool November 26, 2010 Brian Orelli	Get It Together, Johnson & Johnson Another day, another recall.
The Motley Fool January 25, 2008 Mac Greer	Fool Video: Fishing for 4 Bargain Stocks Shares of eBay, Harley-Davidson, Under Armour, and Whole Foods all hit 52-week lows recently. Will they rise again or descend to even lower depths?
The Motley Fool September 2, 2008 Todd Wenning	Supercharge Your Income With These Stocks Dividend stocks offer the best option, but you need to start now.
The Motley Fool August 19, 2010 Brian Orelli	Buffett Is Buying J&J. Should You? It depends on your time horizon.
The Motley Fool January 18, 2012	What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance.
The Motley Fool January 18, 2011 Russ Krull	Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold?
The Motley Fool June 15, 2006 Selena Maranjian	My Dividends Are Bigger Than Yours Your yield may be 2% when mine is a whopping 13%. Here's the secret.
The Motley Fool August 14, 2007 Brian Orelli	A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare.
The Motley Fool May 28, 2010 Brian Orelli	How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem?
The Motley Fool August 27, 2010 Brian Orelli	A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.
The Motley Fool April 21, 2010 Brian Orelli	Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant.
The Motley Fool July 31, 2009 Chris Hill	3 Stocks on Our Radar A hot, steaming cup of stock talk about Microsoft, Apple, and Under Armour, plus more.
The Motley Fool April 29, 2011 David Williamson	Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.
The Motley Fool December 1, 2010 Brian Orelli	We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell.
The Motley Fool June 25, 2010 Brian Orelli	The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error.
Fast Company March 15, 2007	Fast Talk: Testing the Edge Public Radio International's Alisa Miller discusses the quest for weirdness.
The Motley Fool May 26, 2011 Russ Krull	Stocks vs. Bonds for Income: Let's Rumble Investors should ignore bonds, but they should consider stocks for at least part of an income-oriented portfolio.
The Motley Fool January 26, 2010 Brian Orelli	Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years.
The Motley Fool December 7, 2005 Alyce Lomax	Digital Radio Hurries Up Major radio names plan a more rapid rollout of digital radio broadcasting. It's obvious that traditional radio's big names are trying hard to keep up with the times.
The Motley Fool June 16, 2011 Jordan DiPietro	Should You Retire With Johnson Controls? Johnson Controls' valuation, dividends, growth and low volatility can tell us if it has the traits of a good retirement stock.
The Motley Fool September 14, 2009 Brian Orelli	The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool May 17, 2010 Selena Maranjian	Beat Bonds and Still Stay Safe There may be a way for risk-averse investors to keep their nest eggs relatively safe, yet still enjoy bond-beating growth.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool July 9, 2010 Brian Orelli	Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products.
The Motley Fool February 8, 2008 Mac Greer	Fool Video: Super Bowl Stocks and Bear Market Buys Who would win the Super Bowl of stocks? Does Home Depot have the right stuff for a bear market? Are Johnson & Johnson, Proctor & Gamble and Wal-Mart recession-proof? These questions and others are discussed in this video.
The Motley Fool October 13, 2008 Brian Orelli	Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news
The Motley Fool June 20, 2006 Shruti Basavaraj	Doubles Are Better Than Home Runs Loads of investors think they want to find the next home run stock. These potential 10-baggers keep many of us in the investing game. While it's good to aim for the fences, investors should be content with the doubles.